Compare Incyte Corporation (INCY) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vanguard Growth Index Fund ETF — how do they compare? Incyte Corporation trades at $113.59 (market cap $22.85B), while Vanguard Growth Index Fund ETF trades at $91.91 (market cap $384.60B). The key difference: Vanguard Growth Index Fund ETF is far larger — about 16.8× Incyte Corporation's market cap, and Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Vanguard Growth Index Fund ETF for 47 Days on average.
| INCY | VUG | |
|---|---|---|
Market Cap | $22.85B | $384.60B |
Volume | 1,927,029 | 5,662,307 |
Sector | Health | Sector/Thematic |
52-Week High | $129.93 | $92.64 |
52-Week Low | $83.80 | $70.00 |
Typical Hold Time | 33 Days | 47 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
VUG trades at $92.42, down 0.24% on the day, with a bullish technical outlook supported by moving averages but showing overbought conditions on shorter-term RSI readings. The ETF maintains strong long-term performance credentials with 11-12% average annual returns since 2004, though current concentration in mega-cap tech stocks presents both opportunity and risk. Recent dividend activity shows minimal income generation with a $0.09 distribution scheduled for September 2026.
The growth-focused ETF offers exposure to market-leading companies but faces concentration risk with over 36% in three holdings. Long-term investors benefit from Vanguard's low-cost structure and historical outperformance, though near-term technical indicators suggest potential consolidation. Market sentiment remains positive for buy-and-hold strategies despite recent value stock outperformance in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
